Payment overview · 2025
General Payments
$3,488.77
134 reported records · 30 companies
Healthcare provider profile · identity verified
Omid Omidvar, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LOS ALAMITOS, CA · NPI 1184678583
Verified facts
What the public records show
CMS Open Payments records show Omid Omidvar, M.D. received $3,488.77 in general payments during 2025 across 134 reported records.
Novartis Pharmaceuticals Corporation accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Leqembi, Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQEMBI as an associated drug or biological on 4686 records involving 1817 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Leqembi by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Leqembi as an associated drug or biological on 28719 records involving 10254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Leqembi by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gammagard Liquid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trintellix by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $497.17 | 14.2% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $372.22 | 10.7% | 19 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $321.00 | 9.2% | 13 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $240.32 | 6.9% | 8 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $236.62 | 6.8% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $161.10 | 4.6% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $156.54 | 4.5% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $144.50 | 4.1% | 5 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $133.44 | 3.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $124.97 | 3.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $119.28 | 3.4% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $109.23 | 3.1% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $108.97 | 3.1% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $99.68 | 2.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.49 | 2.6% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.93 | 2.4% | 3 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $69.91 | 2.0% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$54.73 | 1.6% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $53.55 | 1.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.25 | 1.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.37 | 1.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $35.00 | 1.0% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $32.31 | 0.9% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $27.75 | 0.8% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.44 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.94 | 0.7% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.68 | 0.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.99 | 0.7% | 1 | 2025 |
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $22.82 | 0.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.57 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,374.25 | 130 |
| Education | $114.52 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $497.17 | 25 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $279.02 | 11 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $236.62 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $236.10 | 12 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $234.35 | 9 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $207.85 | 7 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $144.50 | 5 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $119.28 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $108.97 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $100.52 | 6 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $99.67 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $91.49 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $82.93 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $79.70 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $71.12 | 5 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $66.21 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $56.02 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $53.55 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $45.71 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.33 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $35.37 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $32.44 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $32.31 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $29.53 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $29.47 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $25.68 | 2 | 2025 |
Source payment records
|
|||||
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LEQEMBI leqembi |
2025 | Leqembi | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | LEQEMBI open payments reported associated product |
CMS Open Payments — General Payments 4686 supporting records · 1817 recipient NPIs · example record 1208299730 |
Leqembi · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Leqembi open payments reported associated product |
CMS Open Payments — General Payments 28719 supporting records · 10254 recipient NPIs · example record 1244455613 |
Leqembi · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 223 | 64 |
| Gabapentin | Gabapentin | 203 | 50 |
| Donepezil Hcl | Donepezil Hcl | 182 | 50 |
| Rasagiline Mesylate | Rasagiline Mesylate | 104 | 30 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 102 | 32 |
| Candesartan Cilexetil | Candesartan Cilexetil | 100 | 30 |
| Mirtazapine | Mirtazapine | 87 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 21 |
| Levetiracetam | Levetiracetam | 77 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 74 | 27 |
| Galantamine Er | Galantamine Hbr | 66 | 21 |
| Rivastigmine | Rivastigmine | 62 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 18 |
| Amantadine | Amantadine Hcl | 55 | 14 |
| Primidone | Primidone | 54 | suppressed |
| Belsomra | Suvorexant | 52 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 15 |
| Neupro | Rotigotine | 45 | suppressed |
| Lubiprostone | Lubiprostone | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 12 |
| Pregabalin | Pregabalin | 39 | 11 |
| Baclofen | Baclofen | 38 | 14 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Lamotrigine | Lamotrigine | 36 | 12 |
| Levetiracetam Er | Levetiracetam | 34 | suppressed |
| Modafinil | Modafinil | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | 12 |
| Trazodone Hcl | Trazodone Hcl | 34 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 13 |
| Rytary | Carbidopa/Levodopa | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | 12 |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Droxidopa | Droxidopa | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Dayvigo | Lemborexant | 19 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 19 | suppressed |
| Leqembi | Lecanemab-Irmb | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 17 | suppressed |
| Briviact | Brivaracetam | 16 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 13 | suppressed |
| Nourianz | Istradefylline | 13 | suppressed |
| Ongentys | Opicapone | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Isradipine | Isradipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,488.77 · 134 records | Novartis Pharmaceuticals Corporation | AMPYRA, BOTOX, CREXONT, Fintepla, GOMEKLI, General - DBS, Gocovri, HYQVIA, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, LUMRYZ, Motpoly XR, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, POCKET EEG DEVICE, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, Xeomin | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Leqembi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error